Nanoform Finland Oyj and Herantis Pharma Plc, announced that they have signed a letter of intent to collaborate to seek to enhance nasal drug delivery to the brain of Herantis CDNF and xCDNF therapies (Parkinsons disease) using Nanoforms proprietary biological nanoparticle technology. The planned and non-exclusive collaboration is intended to assess the utility of Nanoforms latest platform technology for biologic drugs. The technology was recently launched, post filing of a provisional patent application with the US Patent Office, to enable production of biological nanoparticles as small as 50 nm. Subject to finalizing definitive agreements, Nanoform will in this partnership carry out, for compensation on standard commercial terms, two Proof of Concept studies on Herantis CDNF and xCDNF molecules leveraging Nanoforms novel platform and its in-house formulation expertise. The goal of the planned collaboration is to increase the probability of success for enhanced BBB (Blood-Brain-Barrier) penetration in the nasal drug delivery route for CDNF and x-CDNF. Nanoform is committed to supporting Herantis in the development of these programs and has undertaken to invest, subject to certain customary conditions, 1,600,000 euros in a planned immediate directed share issue by Herantis.